GI malignancies and precision medicine
Publish place: Third International Private Medical Congress of Iran
Publish Year: 1397
نوع سند: مقاله کنفرانسی
زبان: English
View: 398
متن کامل این Paper منتشر نشده است و فقط به صورت چکیده یا چکیده مبسوط در پایگاه موجود می باشد.
توضیح: معمولا کلیه مقالاتی که کمتر از ۵ صفحه باشند در پایگاه سیویلیکا اصل Paper (فول تکست) محسوب نمی شوند و فقط کاربران عضو بدون کسر اعتبار می توانند فایل آنها را دریافت نمایند.
- Certificate
- من نویسنده این مقاله هستم
این Paper در بخشهای موضوعی زیر دسته بندی شده است:
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
IPMCMED03_093
تاریخ نمایه سازی: 6 خرداد 1398
Abstract:
GI malignancies are a major problem in recent century due to overall poor outcome and high incidence and lack of too effective treatment.The most challenging issue in GI cancer treatment is to find the appropriate drug for the right patient at the right time.In fact it s precision medicine and it focuses on patient tumor genomics profile.In personalized medicine point of view we try to find appropriate target for the treatment.Now we have more knowledge about targeting HER2 in some kinds of GI cancers and the role of KRAS mutation and other biomarkers for better risk stratification and more specific management.NGS helps us to find abnormality in each patient that discriminates them from each other and these abnormalities directed treatment lead to more effective therapy with less cost.However for the majority, finding this type of managing based on the unique mutation isn t too easy and is sometimes so difficult.Personalized medicine is on it s way and it s supposed to be the most effective treatment in future.
Keywords:
Authors
Leila Sadeghi
M.D, Hematologist and Medical Oncologist Assistant professor of SBMU